December 22, 2021 09:40 AM EST
News Briefing

Boston start­up lands $28M, clos­es small biotech buy­out; New longevi­ty fund takes shape

John Carroll

Editor & Founder

Boston-based start­up DermBiont has gone back to the ven­ture well while tack­ing on an­oth­er small buy­out to swell the clin­i­cal pipeline.

The start­up, which raised …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­gen brings in med­ical chief as CFO plans re­tire­ment; Macro­Gen­ics CEO an­nounces de­par­ture

Es­sa’s shares tank as it looks for op­tions af­ter aban­don­ing prostate can­cer drug

UCB's an­ti-tau Alzheimer's pro­gram fails Phase 2 pri­ma­ry end­point, but high­lights pos­i­tive sec­on­daries

Q&A with Obe­si­ty So­ci­ety’s CEO as the field pre­pares for next-gen meds

Fol­low­ing 2019 re­jec­tion, FDA ad­comm votes against Lex­i­con's type 1 di­a­betes and CKD drug

Gar­dasil de­mand in Chi­na sinks, and Mer­ck ex­pects the same next quar­ter

A service from the Financial Times